The much-anticipated sixth edition of ISO 10993-1, the global standard guiding the biological evaluation of medical devices, has officially been released. The updated standard aligns more closely with the risk-based approach of ISO 14971, introducing strengthened emphasis on identifying and mitigating chemical risks associated with medical devices.
The revised ISO 10993-1 outlines enhanced principles for evaluating biological safety through a structured risk management process, ensuring safer materials, improved chemical characterization, and better-defined evaluation pathways for manufacturers.
According to experts in the field, the latest edition reinforces the idea that when a device’s chemical composition is well-understood, its biological risk can be better estimated. This perspective is central to the approach of several toxicology service providers who focus on advanced analytical methods, including mass spectrometry, to support biocompatibility assessments.
The updated document is expected to guide regulatory submissions, laboratory evaluations, and industry best practices for years to come.
Standard: ISO 10993-1
Edition: Sixth Edition
Release Year: 2025
Topic: Biological Evaluation of Medical Devices, Requirements and General Principles for Evaluating Biological Safety
